Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | TACR3 | P29371 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3318358 | 0.87 | MEN1 (0.49) | STSPDE4BMAPK1MEN1KMT2A | |
| SCHEMBL30397321 | 0.85 | STS (0.47) | GSK3BSTSMAPK1MEN1KMT2A | |
| SCHEMBL23982238 | 0.85 | STS (0.47) | GSK3BSTSMAPK1MEN1KMT2A | |
| SCHEMBL16640402 | 0.84 | DPP4 (0.43) | PDE4BMAPK1KDM4EMAPTTHRB | |
| SCHEMBL26102356 | 0.83 | GPR119 (0.49) | PDE4BMAPK1MEN1KMT2AMAPT | |
| SCHEMBL6017253 | 0.83 | GPR119 (0.49) | PDE4BMAPK1MEN1KMT2AMAPT | |
| SCHEMBL16026535 | 0.83 | ESR2 (0.44) | PDE4BMAPK1KMT2AESR2KDM4E | |
| SCHEMBL38662218 | 0.83 | MEN1 (0.47) | PDE4BMAPK1MEN1KMT2ARORC | |
| SCHEMBL31223989 | 0.82 | KDM4E (0.39) | STSPDE4BMAPK1MEN1KMT2A | |
| SCHEMBL17519223 | 0.82 | RORC (0.44) | GSK3BPDE4BMAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240270705-A1 | COMPOUNDS SELECTIVE FOR JAK1 AND METHODS OF USE | VIVIDION THERAPEUTICS, INC. | 2024-08-15 | — | — | US | disclosed |
| WO-2022251280-A1 | COMPOUNDS SELECTIVE FOR JAK1 AND METHODS OF USE | VIVIDION THERAPEUTICS, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| EP-0823906-B1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORP (US) | 2003-07-09 | — | — | EP | disclosed |
| US-5981520-A | USEFUL FOR TREATING ASTHMA, BRONCHOSPASM, ALLERGIES, ANXIETY, COUGHING OR PAIN | SCHERING CORPORATION (US) | 1999-11-09 | — | — | US | disclosed |
| US-5795894-A | TREATMENT OF ASTHMA AND BRONCHOSPASM | SCHERING CORPORATION (US) | 1998-08-18 | — | — | US | disclosed |
| EP-0823906-A1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1998-02-18 | — | — | EP | disclosed |
| WO-1996034864-A1 | PIPERAZINO DERIVATIVES AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1996-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270705-A1 | COMPOUNDS SELECTIVE FOR JAK1 AND METHODS OF USE | JAK2, JAK1, JAK3 | GSK3B 529/4885STS 4352/4885PDE4B 1223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.